| Detailed information |
|---|
| CancerLivER ID | 2024 |
| Biomarker | eIF5 |
| Biomarker Name/Symbol (given in Publication) | eIF5 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarkers for non-virus related HCC and virus related HCC and validated on independent dataset |
| Experimental Condition | Normal vs cancer |
| Cancer type | HBV-associated Hepatocellular carcinoma |
| Regulation | Upregulated in chronic hepatitis B (HBV)-associated HCC |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 28715695 |
| Type of Biomarker | Diagnostic |
| Pathway | phospha- tidylinositol-3-kinases PI3K/AKT/mTOR pathway |
| Cohort | The cohort included 196 (83.4%) male and 39 (16.6%) female patients. Age ranged between 30 and 81 years, with a median of 56 years. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human chronic hepatitis B (HBV)-associated HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |